SCHEMBL27944748

SCHEMBL27944748

[CH2]CCN(CCCCN(CCC(N)C(=O)OCc1ccccc1)C(=O)OCc1ccccc1)C(=O)OCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 1/20 0.53
PAX8 Q06710 1/20 0.53
IDO1 P14902 1/20 0.38
SLC1A3 P43003 1/20 0.37
SLC1A1 P43005 1/20 0.37
SLC1A5 Q15758 4/20 0.36
ANPEP P15144 1/20 0.36
ALDH1A1 P00352 2/20 0.36
SLC15A1 P46059 1/20 0.36
LTA4H P09960 1/20 0.36
LAP3 P28838 1/20 0.36
CCKBR P32239 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL415523 0.89 CCR6 (0.54) CCR6PAX8IDO1SLC1A3SLC1A1
SCHEMBL417986 0.88 CCR6 (0.53) CCR6PAX8IDO1SLC1A3SLC1A1
SCHEMBL417676 0.83 CCR6 (0.52) CCR6PAX8IDO1SLC1A3SLC1A1
SCHEMBL14675316 0.79 IDO1 (0.46) IDO1SLC1A3SLC1A1ANPEPALDH1A1
SCHEMBL7667985 0.79 ALDH1A1 (0.49) IDO1SLC1A3SLC1A1ALDH1A1SLC15A1
SCHEMBL8501765 0.78 CCR6 (0.45) CCR6PAX8IDO1SLC1A3SLC1A1
SCHEMBL27515194 0.78 DPP8 (0.46) IDO1SLC1A3SLC1A1ANPEPALDH1A1
SCHEMBL7893066 0.77 CCR6 (0.41) CCR6PAX8IDO1SLC1A3SLC1A1
SCHEMBL7893100 0.76 CCR6 (0.43) CCR6PAX8IDO1SLC1A3SLC1A1
SCHEMBL759516 0.76 CCR6 (0.66) CCR6PAX8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102131814-B (Poly) aminoalkylaminoalkylamide, alkyl-urea or alkyl-sulfonamide derivatives of epipodophyllotoxins, process for their preparation and their use in therapy as anticancer agents PF MEDICAMENT 2014-03-26 CN disclosed